OmniAb Q4 2022 Earnings Report
Key Takeaways
OmniAb reported Q4 2022 revenue of $35.3 million, a significant increase compared to $15.3 million in Q4 2021, driven by a $25.0 million milestone payment from the first commercial sale of TECVAYLI™ in the U.S. Net income for the quarter was $6.8 million, a substantial improvement from the net loss of $3.1 million in the same period last year.
Revenue for the fourth quarter of 2022 was $35.3 million, compared to $15.3 million for the same period in 2021.
Net income for the fourth quarter of 2022 was $6.8 million, or $0.07 per diluted share, compared to a net loss of $3.1 million, or $0.04 per share, for the same period in 2021.
Signed 13 new licenses in 2022, including one in the fourth quarter with the Wistar Institute.
As of December 31, 2022, the company had 69 active partners with 26 OmniAb-derived programs in clinical development or being commercialized, and a total of 291 programs being pursued or commercialized.
OmniAb
OmniAb
OmniAb Revenue by Segment
Forward Guidance
The Company expects its 2023 year-end cash, cash equivalents and short-term investments balance to be slightly higher than year-end 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income